Henkel of America since Apr 2011
Technical Manager,
Add-Vision, Inc. May 2005 - Apr 2011
Lead Scientist
PolyFuel Oct 2002 - May 2005
Senior scientist, project lead
Canon Development Americas, Inc. Feb 2000 - Sep 2002
Scientist
IBM Almaden Research May 1998 - Jan 2000
Postdoctor
Education:
Carleton University 1992 - 1996
Ph.D., Organic/Polymer Chemistry
Zhejiang University 1982 - 1986
B.Sc., Chemistry
Jianping Chen - Nutley NJ, US Brian Higgins - Nutley NJ, US Kenneth Kolinsky - Nutley NJ, US
International Classification:
A61K039/395 A61K031/498
US Classification:
514249000, 424143100
Abstract:
The present invention provides a method for treating tumors or tumor metastases in a patient, comprising administering to the patient simultaneously or sequentially a therapeutically effective amount of an EGFR kinase inhibitor and irinotecan combination, with or without additional agents or treatments, such as other anti-cancer drugs or radiation therapy. The invention also encompasses a pharmaceutical composition that is comprised of an EGFR kinase inhibitor and irinotecan combination in combination with a pharmaceutically acceptable carrier. A preferred example of an EGFR kinase inhibitor that can be used in practicing this invention is the compound erlotinib HCl (also known as Tarceva™).
Combined Treatment With Oxaliplatin And An Epidermal Growth Factor Receptor Kinase Inhibitor
Jianping Chen - Nutley NJ, US Brian Higgins - Nutley NJ, US Kenneth Kolinsky - Nutley NJ, US
International Classification:
A61K031/498 A61K031/28
US Classification:
514249000, 514492000
Abstract:
The present invention provides a method for treating tumors or tumor metastases in a patient, comprising administering to the patient simultaneously or sequentially a therapeutically effective amount of an EGFR kinase inhibitor and oxaliplatin combination, with or without additional agents or treatments, such as other anti-cancer drugs or radiation therapy. The invention also encompasses a pharmaceutical composition that is comprised of an EGFR kinase inhibitor and oxaliplatin combination in combination with a pharmaceutically acceptable carrier. A preferred example of an EGFR kinase inhibitor that can be used in practicing this invention is the compound erlotinib HCl (also known as Tarceva™).
Dr. Chen graduated from the Beijing Med Univ, Beijing City, Beijing, China in 1986. He works in New York, NY and specializes in Psychiatry. Dr. Chen is affiliated with New York Presbyterian Lower Manhattan Hospital.
New Jersey Anesthesia AssocsNew Jersey Anesthesia Associates PC 94 Old Short Hl Rd STE 103A, Livingston, NJ 07039 9733225512 (phone), 9736609779 (fax)
Education:
Medical School Shanghai Med Univ, Shanghai First Med Univ, Shanghai, China Graduated: 1987
Languages:
English
Description:
Dr. Chen graduated from the Shanghai Med Univ, Shanghai First Med Univ, Shanghai, China in 1987. He works in Livingston, NJ and specializes in Anesthesiology. Dr. Chen is affiliated with Newark Beth Israel Medical Center and Saint Barnabas Medical Center.
Jianping Chen, New York NY
Work:
Mental Hlth. Clin.
268 Canal St, New York, NY 10013 St Barnabas Medical Center
94 Old Short Hills Rd, Livingston, NJ 07039
Jianping Chen, New York NY
Work:
Acnc-Charles B. Rangel Community Health Center
268 Canal St, New York, NY 10013